These results reflect continued execution in our core business coupled with strong progress from our AI-led new product portfolio. In fact, our pure AI ARR is growing at a strong double-digit rate ...
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback